Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Axios
Axios
Health
Caitlin Owens

FDA committee recommends withdrawing Makena for preterm birth prevention

An FDA advisory committee yesterday voted to recommend that Makena, a treatment to prevent women from having a preterm birth, be withdrawn from the market after a study found that it's ineffective, the Wall Street Journal reports.

Backdrop: The FDA approved the drug in 2011, but required a follow-up study. That study came out last week and found that the drug — which has become the standard treatment — doesn't decrease recurrent preterm births.


What they're saying: "At the end of the day we want to be giving pregnant women medications that work and help them and their babies," Adam Urato, chief of maternal-fetal medicine at MetroWest Medical Center in Framingham, Mass., told the Journal. "This drug doesn't work."

Go deeper: When an expensive drug turns out to be a dud

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.